Researchers have discovered a potential way to reverse age-related damage to liver cells in mice and human cell cultures. The study focuses on ferroptosis, a form of iron-dependent cell death that affects hepatocytes in the liver. Gene clusters associated with this process were found in both mice and human cells, suggesting the possibility of reversing aging in affected liver cells through pharmaceutical interventions. The study, published in Nature Aging, found an abundance of genes causing cell death in older liver cells, with ferroptosis implicated in NAFLD/MASLD, a common liver disease affecting millions of people globally.
The authors of the study identified a genetic signature in cells from mice and humans with NAFLD/MASLD, providing a potential target for pharmacological therapy. They conducted experiments on young and old mice fed a diet causing NAFLD/MASLD, with some older mice receiving Ferrostatin-1 injections to test potential therapeutic effects. At the end of the study, older mice receiving Ferrostatin-1 showed young and healthy liver cells, suggesting that aging liver damage may be reversible through targeted interventions. These findings offer hope for developing new therapies for NAFLD/MASLD and potentially other aging-related tissue degeneration conditions affecting various organs.
The senior author of the study, Anna Mae Diehl, MD, emphasized that aging is at least partially reversible and that interventions targeting ferroptosis could mitigate liver damage caused by aging and other conditions. The study suggests that aging exacerbates NAFLD by creating ferroptic stress, and reducing this stress can reverse the damage, making aged livers resemble those of younger individuals. While ferroptosis has dual roles in liver diseases, inhibiting or inducing it may have therapeutic benefits for different conditions, highlighting potential avenues for treatment across various afflictions.
NAFLD/MASLD is a common liver disease affecting a significant portion of the global population, with one in three adults worldwide and 100 million Americans estimated to have the condition. The disease involves the accumulation of fat in liver cells, leading to liver damage and potentially cirrhosis if left untreated. Symptoms of NAFLD/MASLD may include fatigue, weakness, abdominal discomfort, and in children, abdominal pain and skin discoloration. Diagnosis typically involves blood tests and imaging procedures, with treatment focused on lifestyle modifications such as healthy diet and weight management.
The study’s findings offer hope for addressing the aging-related damage to liver cells and potential therapies for NAFLD/MASLD and other related conditions. By targeting ferroptosis and gene clusters associated with aging liver cells, researchers may develop novel interventions to reverse liver damage and improve overall liver health. Further research into the molecular pathways of ferroptosis and potential therapeutic targets may lead to innovative treatments for liver diseases and age-related tissue degeneration affecting multiple organs. As the study demonstrates the partial reversibility of aging-related liver damage, it opens new avenues for combating liver diseases and improving the health of aging individuals.
